BNTX
HEALTHCAREBioNTech SE
$95.26-0.24 (-0.25%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BNTX Today?
No stock-specific AI insight has been generated for BNTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$79.52$124.00
$95.26
Fundamentals
Market Cap$24.1B
P/E Ratio—
EPS$-5.94
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding252.9M
BNTX News
23 articles- BioNTech Announces New ADS Repurchase ProgramYahoo Finance·May 7, 2026
- BioNTech Expands Oncology Trials And Reshapes Manufacturing As Investors Weigh UpsideYahoo Finance·May 6, 2026
- BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls.Yahoo Finance·May 5, 2026
- European Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingYahoo Finance·May 5, 2026
- BioNTech Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- BioNTech Announces First Quarter 2026 Financial Results and Corporate UpdateYahoo Finance·May 5, 2026
- European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for WeekYahoo Finance·May 1, 2026
- Moderna's Legal Hit Steals Spotlight From Strong SalesBenzinga·May 1, 2026
- European Equities Traded in the US as American Depositary Receipts Track Lower in Monday TradingYahoo Finance·Apr 27, 2026
- BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage ModelsYahoo Finance·Apr 24, 2026
- Why BioNTech (BNTX) Is Up 9.2% After Strong Phase 2 HER2 ADC Data In Endometrial CancerYahoo Finance·Apr 23, 2026
- BioNTech (BNTX) Price Target Raised Following Successful T-Pam DataYahoo Finance·Apr 23, 2026
- Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of LanifibranorGlobeNewswire Inc.·Apr 22, 2026
- BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?Yahoo Finance·Apr 22, 2026
- BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026Yahoo Finance·Apr 21, 2026
- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsightGlobeNewswire Inc.·Apr 16, 2026
- Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 EarningsYahoo Finance·Apr 15, 2026
- BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial CancerYahoo Finance·Apr 11, 2026
- How The BioNTech (BNTX) Story Is Shifting With New Leadership And Post COVID Pipeline BetsYahoo Finance·Apr 8, 2026
- European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday TradingYahoo Finance·Apr 7, 2026
- BMO Capital Cuts PT on BioNTech SE (BNTX) to $128 From $143 – Here’s WhyYahoo Finance·Mar 31, 2026
- 3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next247 Wall St·Mar 30, 2026
- BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung CancerYahoo Finance·Mar 24, 2026
All 23 articles loaded
Price Data
Open$91.75
Previous Close$95.50
Day High$96.05
Day Low$90.79
52 Week High$124.00
52 Week Low$79.52
52-Week Range
$79.52$124.00
$95.26
Fundamentals
Market Cap$24.1B
P/E Ratio—
EPS$-5.94
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding252.9M
About BioNTech SE
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—